Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.50 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 2/20 | 0.38 |
| ▸ | PDE2A | O00408 | 2/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12609945 | 1.00 | USP30 (0.50) | USP30EPHA2USP2SMN1; SMN2GPR119 | |
| SCHEMBL30382351 | 1.00 | USP30 (0.50) | USP30EPHA2USP2SMN1; SMN2GPR119 | |
| SCHEMBL12609675 | 1.00 | USP30 (0.50) | USP30EPHA2USP2SMN1; SMN2GPR119 | |
| SCHEMBL7034848 | 0.89 | SMN1; SMN2 (0.45) | USP30USP2SMN1; SMN2GPR119 | |
| SCHEMBL12609869 | 0.87 | NR1H2 (0.46) | USP30USP2SMN1; SMN2GPR119DPP4 | |
| SCHEMBL12610149 | 0.87 | EPHA2 (0.43) | USP30EPHA2USP2SMN1; SMN2RORC | |
| SCHEMBL12610113 | 0.87 | EPHA2 (0.43) | USP30EPHA2USP2SMN1; SMN2RORC | |
| SCHEMBL12609865 | 0.87 | NR1H2 (0.46) | USP30USP2SMN1; SMN2GPR119DPP4 | |
| SCHEMBL14150500 | 0.87 | NR1H2 (0.46) | USP30USP2SMN1; SMN2GPR119DPP4 | |
| SCHEMBL12610112 | 0.87 | EPHA2 (0.43) | USP30EPHA2USP2SMN1; SMN2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2688870-B1 | HETEROCYCLIC AMINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-02-01 | — | — | EP | disclosed |
| US-20160272626-A1 | PYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-09-22 | — | — | US | disclosed |
| EP-2917211-A1 | PYRAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2015-09-16 | — | — | EP | disclosed |
| EP-2718271-B1 | SUBSTITUTED BENZAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2015-08-12 | — | — | EP | disclosed |
| US-9029370-B2 | Substituted benzamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-8802673-B2 | Heterocyclic amine derivatives | Hoffmann-La Roche Inc (US) | 2014-08-12 | — | — | US | disclosed |
| WO-2014072257-A1 | PYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-05-15 | — | — | WO | disclosed |
| EP-2718271-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-04-16 | — | — | EP | disclosed |
| EP-2688870-A1 | HETEROCYCLIC AMINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-01-29 | — | — | EP | disclosed |
| WO-2012168265-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | disclosed |
| US-20120316165-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-12-13 | — | — | US | disclosed |
| WO-2012126922-A1 | HETEROCYCLIC AMINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-27 | — | — | WO | disclosed |
| US-20120245172-A1 | HETEROCYCLIC AMINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245172-A1 | HETEROCYCLIC AMINE DERIVATIVES | TAAR1, TAAR5, MTNR1A | USP30 4358/4885EPHA2 987/4885USP2 4753/4885 |
| US-20160272626-A1 | PYRAZINE DERIVATIVES | HCRTR2, PER2, HCRTR1 | USP30 4302/4885EPHA2 3486/4885USP2 4263/4885 |
| US-20120316165-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | NPY4R, PER2, NPY1R | USP30 4247/4885EPHA2 3596/4885USP2 4711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.